Effects of isoflavone-containing soya protein on ex vivo cholesterol efflux, vascular function and blood markers of CVD risk in adults with moderately elevated blood pressure: a dose-response randomised controlled trial.
Effects of isoflavone-containing soya protein on ex vivo cholesterol efflux, vascular function and blood markers of CVD risk in adults with moderately elevated blood pressure: a dose-response randomised controlled trial.
复制标题
DOI：
10.1017/s000711451700143x
复制
发表时间：
2017-05
期刊：
影响因子：
--
通讯作者：
Kris-Etherton PM
中科院分区：
文献类型：
--
作者：
Richter CK;Skulas-Ray AC;Fleming JA;Link CJ;Mukherjea R;Krul ES;Kris-Etherton PM
新出现的CVD风险因素（例如HDL功能和中心血液动力学）可能是满足LDL-胆固醇和血压（BP）目标的个体经历的残余CVD风险的原因。最近的证据表明，这些新出现的风险因素可以通过富含多酚的干预措施（如大豆）来改变，但需要进行更多的研究。本研究旨在研究含胆固醇的大豆蛋白分离物（递送25和50 g/d大豆蛋白）对HDL功能（即离体胆固醇流出）、大血管功能和CVD风险的血液标志物的影响。在随机交叉设计中，肱动脉血压中度升高（平均收缩压= 129（SEM 9）mmHg;平均舒张压= 82.5（SEM 8.4）mmHg）的中年成人（n 20;平均年龄= 51.6（SEM 6.6）岁）消耗0（对照），25和50 g/d大豆蛋白。大豆粉和对照粉各食用6周，治疗期之间有2周的依从性中断。在基线和每个补充期后获得血液样品和血管功能测量。与25 g/d大豆蛋白相比，补充50 g/d大豆蛋白显著降低了肱动脉舒张压（-2.3 mmHg）（Tukey校正P = 0.03），但对照组没有。与碳水化合物对照组相比，大豆补充剂并没有改善离体胆固醇流出、大血管功能或其他CVD风险的血液标志物。需要进一步的研究来澄清对这些CVD风险因素的影响是否取决于参与者的相对健康状况和/或雌马酚产生能力。
Emerging CVD risk factors (e.g. HDL function and central haemodynamics) may account for residual CVD risk experienced by individuals who meet LDL-cholesterol and blood pressure (BP) targets. Recent evidence suggests that these emerging risk factors can be modified by polyphenol-rich interventions such as soya, but additional research is needed. This study was designed to investigate the effects of an isoflavone-containing soya protein isolate (delivering 25 and 50g/d soya protein) on HDL function (i.e. ex vivo cholesterol efflux), macrovascular function and blood markers of CVD risk. Middle-aged adults (n 20; mean age = 51.6 (SEM 6.6) years) with moderately elevated brachial BP (mean systolic BP = 129 (SEM 9) mmHg; mean diastolic BP = 82.5 (SEM 8.4)mmHg) consumed 0 (control), 25 and 50g/d soya protein in a randomised cross-over design. Soya and control powders were consumed for 6 weeks each with a 2-week compliance break between treatment periods. Blood samples and vascular function measures were obtained at baseline and following each supplementation period. Supplementation with 50 g/d soya protein significantly reduced brachial diastolic BP (−2.3 mmHg) compared with 25 g/d soya protein (Tukey-adjusted P = 0.03) but not the control. Soya supplementation did not improve ex vivo cholesterol efflux, macrovascular function or other blood markers of CVD risk compared with the carbohydrate-matched control. Additional research is needed to clarify whether effects on these CVD risk factors depend on the relative health of participants and/or equol producing capacity.